U.S., Oct. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07891377) titled 'HEC53856 Tablets for Chemotherapy-induced Anemia in Non-myeloid Malignancies' on Oct. 14.
Brief Summary: A Phase II clinical trial to evaluate the efficacy and safety of different dosing regimens of HEC53856 tablets compared to rHuEPO injection in participants of the CIA trial.
Study Start Date: Dec., 2026
Study Type: INTERVENTIONAL
Condition:
Chemotherapy-induced Anemia
Non-Myeloid Malignancy
Intervention:
DRUG: HEC53856 tablet
The experimental cohort is divided into four groups: 20 mg once a day (QD) group, 40 mg QD group, 60 mg QD group, and 100 mg three times a week [TIW] group. Participants in the experimental cohort wil...